Filters: Keyword is Drug Therapy, Combination [Clear All Filters]
"When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study." Annals of internal medicine 154, no. 8 (2011): 509-15. Abstract
"Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 48, no. 8 (2009): 1138-51. Abstract
"Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 38 Suppl 5 (2004): S421-8. Abstract
"Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran." International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 9, no. 6 (2005): 317-22. Abstract
"Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy." Journal of acquired immune deficiency syndromes (1999) 31, no. 1 (2002): 27-37. Abstract
"Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers." HIV medicine 11, no. 2 (2010): 143-51. Abstract
"Top stories of 2004. Nevirapine and efavirenz: similar efficacy, different toxicities, and better separately than combined." AIDS clinical care 17, no. 1 (2005): 5.
"Timing of initiation of antiretroviral drugs during tuberculosis therapy." The New England journal of medicine 362, no. 8 (2010): 697-706. Abstract
"Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir." AIDS (London, England) 20, no. 5 (2006): 783-4.
"Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8." The Journal of infectious diseases 191, no. 3 (2005): 324-32. Abstract
"The survival benefits of AIDS treatment in the United States." The Journal of infectious diseases 194, no. 1 (2006): 11-9. Abstract
"The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis." South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 100, no. 12 (2010): 808-9.
"Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET." Journal of hepatology 62, no. 2 (2015): 286-93. Abstract
"Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects." AIDS research and human retroviruses 26, no. 10 (2010): 1047-9.
"Report from the 13th retrovirus conference. Antiretroviral therapy in resource-limited settings." AIDS clinical care 18, no. 4 (2006): 38.
"Report from the 12th Retrovirus Conference. Tuberculosis." AIDS clinical care 17, no. 4 (2005): 40-1.
"Report from the 12th Retrovirus Conference. HIV/AIDS in resource-limited settings." AIDS clinical care 17, no. 4 (2005): 39-40.
"Report from the 12th Retrovirus Conference. Adherence." AIDS clinical care 17, no. 4 (2005): 36.
"Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 11, no. 5 (2008): 975-9. Abstract
"Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements." AIDS (London, England) 23, no. 16 (2009): 2199-208. Abstract
"A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain." Addictive behaviors 33, no. 1 (2008): 173-9. Abstract
"Preexposure chemoprophylaxis for HIV prevention." The New England journal of medicine 364, no. 14 (2011): 1374; author reply 1374-5.
"Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals." Clinical pharmacokinetics 44, no. 1 (2005): 99-109. Abstract
"A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting." Journal of acquired immune deficiency syndromes (1999) 36, no. 4 (2004): 929-34. Abstract
"A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298)." AIDS research and human retroviruses 18, no. 10 (2002): 699-704. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir." AIDS patient care and STDs 26, no. 6 (2012): 312-9. Abstract
"Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 46, no. 6 (2008): 941-5. Abstract
"Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently." AIDS clinical care 17, no. 10 (2005): 98. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model." Annals of internal medicine 148, no. 3 (2008): 178-85. Abstract
"Hepatitis C treatment completion rates in routine clinical care." Liver international : official journal of the International Association for the Study of the Liver 30, no. 2 (2010): 240-50. Abstract
"Evaluation of multiple failure time analyses of observational data in patients treated for HIV." HIV clinical trials 6, no. 2 (2005): 81-91. Abstract
"Effect of persistent moderate viremia on disease progression during HIV therapy." Journal of acquired immune deficiency syndromes (1999) 37, no. 1 (2004): 1147-54. Abstract
"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals." AIDS (London, England) 24, no. 1 (2010): 123-37. Abstract
"Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?" AIDS (London, England) 22, no. 18 (2008): 2481-92. Abstract
"Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection." AIDS and behavior 12, no. 6 (2008): 852-9. Abstract
"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial." The Lancet infectious diseases 12, no. 9 (2012): 671-7. Abstract
"Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease." Journal of acquired immune deficiency syndromes (1999) 39, no. 1 (2005): 69-77. Abstract
"Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan Africa." The American journal of tropical medicine and hygiene 92, no. 3 (2015): 555-60. Abstract
"Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 47, no. 7 (2008): 952-61. Abstract
"Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial." Annals of internal medicine 152, no. 11 (2010): 704-11. Abstract
"Characteristics of nausea reported by HIV-infected patients initiating combination antiretroviral regimens." Clinical nursing research 11, no. 1 (2002): 71-88. Abstract
"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 19, no. 1 (2010): 53-8. Abstract
"Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV." The Journal of antimicrobial chemotherapy 58, no. 6 (2006): 1299-302. Abstract
"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial." Archives of general psychiatry 68, no. 12 (2011): 1238-46. Abstract
